United Therapeutics Corp. (UTHR) Stock Can 'Continue to Grind Higher' — UBS

UBS analyst Ashwani Verma reiterated a Buy rating and $560.00 price target on United Therapeutics Corp. (NASDAQ: UTHR).

The analyst commented, "UTHR stock reacted pretty favorably to positive TETON-2 results; however, did not meet the expectation for outperformance of some investors based on our incomings. On the positive side, we believe that IPF study results unveiled a $3-4bn peak sales opportunity - this was also a mostly unanticipated positive as Street expectations for IPF success were fairly low. On the negative side, some investors are split on IPF opportunity due to impending competition from Insmed (covered by Trung Huynh) or Liquidia (not covered). This could be the reason why some investors are thinking about Tyvaso IPF commercial opportunity differently vs lets say an unencumbered asset with clean IP story. We believe UTHR stock can continue to grind higher as the story draws more LO interest from investors that would want to own the IPF launch/ further de-risking. Potential sources of near-term upside can come from: 1) TETON-2 detailed data. 2) Legal updates on '327 ILD patent."

For an analyst ratings summary and ratings history on United Therapeutics Corp. click here. For more ratings news on United Therapeutics Corp. click here.

Shares of United Therapeutics Corp. closed at $396.50 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Critical One Energy closes second tranche of flow-through placement
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)